Zobrazeno 1 - 10
of 1 388
pro vyhledávání: ''
Autor:
Tevriz Dilan Demir, Ayca Sayi-Yazgan, Umit Ince, Sinem Oktem-Okullu, Nogayhan Seymen, Arzu Tiftikçi, Nurdan Tözün, Ugur Sezerman, Sawsan Sudqi Said, Fatma Tokat, Elif Merve Aydın, Bahattin Çiçek
Publikováno v:
Immunology Letters. 239:1-11
Background The progression to gastric cancer has been linked to chronic infection with Helicobacter pylori (H. pylori). Immune checkpoint inhibitors (programmed cell death -1, PD-1; programmed cell death –ligand 1, PD-L1) have a role in cancer immu
Autor:
Amel Mezlini, Inès Zidi, Hadda-Imene Ouzari, Daria Bortolotti, Ines Zemni, Hanene Chelbi, Wafa Babay, Hamza Ben Yahia, Roberta Rizzo, Nadia Boujelbene
Publikováno v:
HLA. 98:357-365
HLA-G is a non-classical major histocompatibility complex class Ib molecule. Its expression has been described in various cancer types, including ovarian cancer. HLA-G molecule has been implicated in immune escape and in progression of ovarian tumor
Autor:
Christelle Le Dantec, Cristina Adela Iuga, Ioana-Ecaterina Pralea, Melanie Cornen, Wesley H. Brooks, Jacques-Olivier Pers, Hussam Saad, Tiffany Bergot, Adrian Tempescul, Anne Bordron, Delphine G. Bernard, Jean-Christophe Ianotto, Cristina Bagacean, Mihnea Zdrenghea, Christian Berthou, Yves Renaudineau
Publikováno v:
Journal of Leukocyte Biology
Journal of Leukocyte Biology, 2022, 111 (2), pp.313-325. ⟨10.1002/JLB.4HI0620-392R⟩
Journal of Leukocyte Biology, 2022, 111 (2), pp.313-325. ⟨10.1002/JLB.4HI0620-392R⟩
Chronic lymphocytic leukemia (CLL) is characterized by significant biologic and clinical heterogeneity. This study was designed to explore CLL B-cells’ proteomic profile in order to identify biologic processes affected at an early stage and during
Autor:
Henghui Zhang, Wei Zhou, Chao Wu, Ruyan Xie, Xianchao Guo, Jun Ji, Lei Zhang, Chenhong Peng, Fei Yuan, Ying Yang, Chao Wang, Min Shi, Jun Zhang
Publikováno v:
Cancer Immunology, Immunotherapy
Objective To investigate the molecular characteristics in tumor immune microenvironment that affect long-term survival of patients with pancreatic adenocarcinoma (PAAD). Methods The tumor related genetic features of a female PAAD patient (over 13-yea
Autor:
Jan Budczies, Cornelius F. Waller, Amanda Tufman, Martina Kirchner, Torsten Goldmann, Albrecht Stenzinger, Peter Schirmacher, Petros Christopoulos, Michael Meister, Mark Kriegsmann, Michael Thomas, Martin Reck, Solange Peters, Klaus Kluck, Hauke Winter, Julia Glade, Daniel Kazdal, Stefan Fröhling, Michael Allgäuer, Thomas Muley, Felix J.F. Herth, CP Heußel, Martin Wermke
Publikováno v:
Cancer Immunology, Immunotherapy
Introduction The advent of immune checkpoint blockade (ICB) has led to significantly improved disease outcome in lung adenocarcinoma (ADC), but response of ALK/EGFR-positive tumors to immune therapy is limited. The underlying immune biology is incomp
Autor:
Ulrich Jaeger, Marek Borsky, Jan Oppelt, Laura Z. Rassenti, Medhat Shehata, Václav Šeda, Thomas J. Kipps, Gabriela Pavlasova, Jennifer R. Brown, Daniel Filip, Kvetoslava Liskova, Šárka Pospíšilová, Eva Vojackova, Lenka Kostalova, Matthew S. Davids, Marek Mráz, Katerina Cerna, Sonali Sharma, Jiri Mayer, Andrea Janíková, Pedro Faria Zeni, Stacey M. Fernandes, Veronika Šandová, Laura Ondrisova, Michael Doubek, Leos Kren
Publikováno v:
Blood
B-cell receptor (BCR) signaling and T-cell interactions play a pivotal role in chronic lymphocytic leukemia (CLL) pathogenesis and disease aggressiveness. CLL cells can use microRNAs (miRNAs) and their targets to modulate microenvironmental interacti
Autor:
Sahra Pajenda, Maximilian J. Mair, Adelheid Wöhrer, Barbara Kiesel, Ayseguel Ilhan-Mutlu, Matthias Preusser, Ludwig Wagner, Karin Dieckmann, Anna S. Berghoff, Georg Widhalm, Christine Marosi
Publikováno v:
Cancer Immunology, Immunotherapy
Purpose In primary brain tumors, the efficacy of immune-modulating therapies is still under investigation as inflammatory responses are restricted by tight immunoregulatory mechanisms in the central nervous system. Here, we measured soluble PD-L1 (sP
Autor:
Weibin Hou, Jian Huang, Kun Xia, Meihua Yang, Meng Yang, Junyu Chen, Bo Wang, Tianxin Lin, Wenlong Zhong, Bingkun Zhou, Xiaofei Wang, Hao Yu
Publikováno v:
Cancer Immunology, Immunotherapy. 70:2657-2668
The expression status of programmed cell death-ligand 1/programmed cell death 1 (PD-L1/PD-1) and the infiltration of CD8+ T cells in tumor tissues are considered to be related to immunotherapy efficacy and patient prognosis. The purpose of this study
Autor:
Pedro Rocha, Dzifa Y. Douse, Lixia Diao, Humam Kadara, Jianjun Zhang, Debora A. Ledesma, Jose Luis Solorzano, John V. Heymach, Ruth Salazar, Luisa M. Solis, Neda Kalhor, Barbara Mino, J. Jack Lee, Don L. Gibbons, Cesar A. Moran, David C. Rice, Carmen Behrens, Pamela Villalobos, Ara A. Vaporciyan, Jiexin Zhang, Hitoshi Dejima, Annikka Weissferdt, Kyle G. Mitchell, Tina Cascone, Edwin Parra-Cuentas, Boris Sepesi, Xiuning Le, Ignacio I. Wistuba
Publikováno v:
Cancer Immunology, Immunotherapy
Introduction CD73 is a membrane-bound enzyme crucial in adenosine generation. The adenosinergic pathway plays a critical role in immunosuppression and in anti-tumor effects of immune checkpoint inhibitors (ICI). Here, we interrogated CD73 expression
Autor:
Kerry S. Campbell, R. Katherine Alpaugh, Alexander W. MacFarlane, Ho Man Yeung, Paul F. Engstrom, Essel Dulaimi, Arvind Dasari, Namrata Vijayvergia
Publikováno v:
Cancer Immunol Immunother
High grade neuroendocrine neoplasms (G3 NENs) are rare aggressive tumors with limited treatment options. Twenty-one previously treated patients with metastatic extra-pulmonary G3 NENs were treated with pembrolizumab. Baseline tumor samples were asses